Anbesol Cold Sore Therapy
NDC Package 0573-0246-25
Package Information
Anbesol Cold Sore Therapy is to open tube, cut tip of the tube on score mark with scissorsadults and children 2 years of age and older: apply to the affected area not more than 3 to 4 times dailychildren under 12 years of age: adult supervision should be given in the use of this productchildren under 2 years of age: consult a doctor. Marketed by Glaxosmithkline Consumer Healthcare Holdings (us) Llc, this product is identified by NDC 0573-0246 and is authorized under FDA application part348.
Identification & Billing
- RxCUI: 1006096 - allantoin 1 % / benzocaine 20 % / camphor 3 % / petrolatum 64.9 % Topical Ointment
- RxCUI: 1006096 - allantoin 0.01 MG/MG / benzocaine 0.2 MG/MG / camphor 0.03 MG/MG / petrolatum 0.649 MG/MG Topical Ointment
- RxCUI: 1006096 - allantoin 1 % / benzocaine 20 % / camphor 3 % / petrolatum, white 64.9 % Topical Ointment
- RxCUI: 1052620 - Anbesol Cold Sore Therapy 1 % / 20 % / 3 % / 64.9 % Topical Ointment
- RxCUI: 1052620 - allantoin 0.01 MG/MG / benzocaine 0.2 MG/MG / camphor 0.03 MG/MG / petrolatum 0.649 MG/MG Topical Ointment [Anbesol Cold Sore Therapy]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0573 - Glaxosmithkline Consumer Healthcare Holdings (us) Llc
- 0573-0246 - Anbesol Cold Sore Therapy
- 0573-0246-25 - 1 TUBE in 1 BLISTER PACK / 9 g in 1 TUBE
- 0573-0246 - Anbesol Cold Sore Therapy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0573-0246). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0573-0246-25 identifies a specific commercial package of 1 tube in 1 blister pack / 9 g in 1 tube of Anbesol Cold Sore Therapy, labeled by Glaxosmithkline Consumer Healthcare Holdings (us) Llc. This product is billed per "GM" gram and contains an estimated amount of 9 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Glaxosmithkline Consumer Healthcare Holdings (us) Llc on May 09, 2006. The current certification is valid through December 31, 2021.
How is this Glaxosmithkline Consumer Healthcare Holdings (us) Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00573024625. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 9 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
